The FDA cleared Viridian Therapeutics’ Lumvoa (veligrotug-vvze) for thyroid eye disease, giving the IGF-1R antagonist a route into both active and chronic phases. The approval sets up competition with Amgen’s Tepezza, while also positioning Lumvoa as Viridian’s first commercial product.